TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03472326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9131
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9131
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9131
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9131
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9131
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Tablet(s) administered orally once daily
Study: NCT03374787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fusion Sound Processor
Description: Sound Processor
Study: NCT00745537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: repeated mood measures and phone depression care management
Description: The adolescent mothers will be assigned a depression care management who will support the mother in making choices about depression treatment, educate about treatment options, discuss barriers and solutions, counsel to comply with treatment recommendations, and assisted to problem-solve if failure to respond occurs.
Study: NCT02951078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thulium Laser en Bloc Resection of bladder tumor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical transurethral resection of bladder tumor
Study: NCT03670563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short foot exercise protocol
Description: Exercises that target intrinsic foot muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short foot exercise plus NMES
Description: Exercises that target intrinsic foot muscles supplemented by NMES for muscle re-education
Study: NCT04007016

Intervention type: PROCEDURE
Intervention: a new osteotomy from the inner L shaped iliac osteotomy
Description: There were two ostectomies were used in the osteotomy. The first was was a cured and 5mm width and the second one was straight 1.5cm width. All the directions was started from the inner to outer just a bove the triradiate cartilage and its shape likeL
Study: NCT01124279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 853
Description: Single dose administration of AMG 853 in tablet form to healthy adult subjects
Study: NCT02357017

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NaCl tablets
Study: NCT03778788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet group
Description: The participants will additionally receive a Hong Kong version LIP booklet to take home and use for 24 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet group
Description: The participants will additionally receive a Hong Kong version LIP booklet to take home and use for 24 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 24 weeks.
Study: NCT00901459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS Condition
Description: Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS Location Control Condition
Description: Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS Frequency Control Condition
Description: High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
Study: NCT02543918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered by SQ injection
Study: NCT01285804

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cuffed ETT
Description: Kimberly Clark

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncuffed ETT
Description: Kimberly Clark
Study: NCT02543918

Intervention type: DRUG
Group type: OTHER
Intervention: Boostrix®
Description: Administered by IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: Administered by IM injection

Intervention type: DRUG
Group type: OTHER
Intervention: Pneumovax®23
Description: Administered by IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pneumovax®23
Description: Administered by IM injection
Study: NCT03557775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training (IMST)
Description: IMST will be conducted using an inspiratory pressure threshold trainer (Philips Respironics® Threshold IMT or POWERbreathe® Medic Plus), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST)
Description: EMST will be conducted using an expiratory pressure threshold trainer (EMST150®), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing out forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
Study: NCT03903419

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.
Description: This study is a non-randomized, prospective, feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy for glioblastoma.~Patients with a MRI performed since the end of the radiotherapy until 12 months of follow up after the end of radiotherapy, will be referred for both 68Ga-PSMA and 18F-FDOPA PET-CT, whatever the conclusion of the MRI (post radiation modifications, relapse or doubtful MRI).
Study: NCT03419754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose
Study: NCT00610532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenytoin
Description: intravenous phenytoin (15 mg/kg) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenytoin and probenecid
Description: intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
Study: NCT04689087

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTFields
Description: For patients with relapsed GBM, before receiving electric field treatment, the patient can be re-operated, and TTFields+BPC chemotherapy is used after surgery
Study: NCT03950284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate loading with all on four technique in FFF
Description: All cases will undergo surgery under local regional anesthesia. Injection of local anaesthesia (Articaine 4% and 1:100000 epinephrine) for regional infiltration. Sequential drilling then insertion of the dental implant fixtures and abutments on which the prefabricated temporary prosthesis will be fixed.
Study: NCT02306356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavior Therapy
Study: NCT03419754

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fidgetting
Description: low intensity physical activity (fidgetting)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fidgetting
Description: low intensity physical activity (fidgetting)
Study: NCT02618876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine plus Bupivacaine
Description: Addition of caudal Nalbuphine to the standard Bupivacaine

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: Caudal Bupivacaine is the standard of care will be considered as a control
Study: NCT00422162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: 60 mg once or twice a day, by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: 60 mg once or twice a day, by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule by mouth
Study: NCT03256305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: personalized rTMS+drug treatment
Description: High frequency（10HZ）stimulation of brain regions corresponding to lesion, low-frequency （1HZ）stimulation of the contralateral brain, intensity=90%MT（motor thresholds). Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day, 1 times a day ,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rTMS +drug treatment
Description: Traditional rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz; localization of right DLPFC: frequency=1 Hz, intensity=90%MT, Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day,1 times a day,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
Study: NCT01526486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videoscopic procedure
Description: Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open, traditional approach
Description: Open surgical procedure, with sartorius muscle transfer.
Study: NCT04508829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-EGFR monoclonal antibody
Description: The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy in locally advanced oropharyngeal carcinoma with induced chemotherapy resistance. The specific treatment description is included in arm description.
Study: NCT01630239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser ablation
Description: Laser ablation of hepatic tumors
Study: NCT03370094

Intervention type: DIAGNOSTIC_TEST
Intervention: Audio-video-streaming of suspected stroke symptoms and signs
Description: The diagnosis based on the patient evaluation by end-to-end encrypted real-time video will be compared to the gold standard, consisting of an in-person neurological examination by a stroke specialist in patients with suspected acute stroke.
Study: NCT01429168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: One 60-mg tablet orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: One 60-mg tablet orally daily
Study: NCT03557775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Exercises
Description: Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Exercises
Description: Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice Exercises
Description: Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.
Study: NCT02270021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Mobile Application (ProvAPP)
Description: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ProvAPP + Patient Educational Tool (Tab)
Description: Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
Study: NCT04179929

Intervention type: DRUG
Group type: OTHER
Intervention: Pediatric-type of chemotherapy
Description: Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: allogeneic HSCT
Description: allogeneic HSCT
Study: NCT01203982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 5mg/day for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 40mg/day for one year
Study: NCT00062829

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teen Driving: Program for parents
Description: A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
Study: NCT03961932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linzagolix
Description: A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
Study: NCT01429168

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for etoricoxib
Description: One 60-mg tablet orally daily
Study: NCT03961932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linzagolix
Description: A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linzagolix
Description: A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linzagolix
Description: A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linzagolix
Description: A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
Study: NCT03349203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day by mouth for 8 weeks as neoadjuvant therapy before surgery and 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
Study: NCT04115488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) infusions
Description: Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) infusions
Description: Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
Study: NCT03971968

Intervention type: PROCEDURE
Intervention: Skin replacement with artificial skin
Description: Integra® Dermal Regeneration Template is a bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer to control moisture loss from the wound. The silicone outer layer temporarily closes the wound to ward off infection and control fluid and heat loss. As skin cells migrate into the matrix the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, new dermal skin is produced and the silicone layer can be removed. A thin skin graft of the person's epidermis is applied to the wound area to complete the procedure. In total, the two surgical procedures are typically completed within 30 days. A person is left with flexible growing skin and minimal damage at the skin graft donor sites.
Study: NCT02662075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-cigarette/tobacco Smoking Exposure
Description: Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
Study: NCT03044327

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LPS challenge
Description: LPS inhalation and bronchial instillation
Study: NCT04009122

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IGEN0206
Description: Group A

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group B
Study: NCT00598442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
Study: NCT01403636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form:capsule Route of administration: oral
Study: NCT02662140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Applictaion
Description: Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW.~Component 2: Focuses on targeting factors putative related to poor HW implementation within the Do process